What Happened?
Shares of vaccine biotechnology company Novavax (NASDAQ: NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.
The biotechnology firm posted a loss of 6 cents per share, which was significantly narrower than the consensus estimate of a 25-cent loss. Quarterly revenues totaled $139.5 million, easily surpassing the expected $69.5 million. While sales were down 79% compared to the same period in the previous year, investors focused on the strong performance relative to expectations.
The company also highlighted that its business is increasingly tied to partners, who now have the rights to evaluate its proprietary Matrix-M technology in over 30 fields, including infectious diseases and oncology, signaling potential for future growth.
Is now the time to buy Novavax? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Novavax’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. But moves this big are rare even for Novavax and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 2 months ago when the stock gained 24.4% on the news that the company reported fourth-quarter financial results that significantly beat analyst expectations.
Novavax announced revenue of $147.1 million, up approximately 67% from the prior year's quarter and well ahead of forecasts. The company also posted a surprise profit with earnings per share (EPS) of $0.11. This was a significant beat, as analysts had expected a loss of $0.49 per share, and it marked a notable turnaround from a loss of $0.51 per share in the same period of the previous year. The strong top-line growth and unexpected profitability drove investor optimism.
Novavax is up 47% since the beginning of the year, and at $10.48 per share, it is trading close to its 52-week high of $11.19 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at only $65.28.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
